|
04.07.25 - 11:42
|
Wie BioNTech, Pfizer und Co? Hammer-Gerüchte um Astrazeneca (Der Aktionaer)
|
|
Der britisch-schwedische Pharma-Konzern Astrazeneca zählt zu den führenden Anbietern von Krebsmedikamenten. Zum Portfolio gehört unter anderem der Blockbuster Tagrisso, der zur Behandlung von Lungenkrebs zum Einsatz kommt. Das Unternehmen will nun einem Bericht zufolge den Bereich mit einem milliardenschweren Deal verstärken....
|
|
|
|
|
|
|
|
|
|
27.06.25 - 01:06
|
More Fetal Losses Than Expected After Pfizer COVID-19 Vaccination In Israel: Study (ZeroHedge)
|
|
More Fetal Losses Than Expected After Pfizer COVID-19 Vaccination In Israel: Study
Authored by Zachary Stieber via The Epoch Times (emphasis ours),
A higher-than-expected number of miscarriages and other forms of fetal loss were associated with COVID-19 vaccinations in Israel, a new study has revealed.
A medic prepares a dose of the Pfizer-BioNTech COVID-19 vaccine in Netanya, Israel, on Jan. 5, 2022. Jack Guez/AFP via Getty Images
Researchers found 13 fetal losses—four more than the nine expected—for every 100 pregnant women who received a COVID-19 vaccine during weeks eight to 13 in pregnancy, according to the study, which was published as a preprint on the medRxiv server.
Most people in Israel, including pregnant women, received the Pfizer-BioNTech COVID-19 vaccine.
Pfizer did not respond by publication time to a request for comment.
The team behind the study includes Retsef Levi, a Massachusetts Institute of Technology researcher who was recently named to the committee that advises the...
|
|
25.06.25 - 14:39
|
Expert Outlook: BioNTech Through The Eyes Of 11 Analysts (Benzinga)
|
|
Latest Ratings for BNTX
DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022Redburn PartnersUpgradesSellNeutral
View More Analyst Ratings for BNTX
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
16.06.25 - 16:18
|
BioNTech Aktie: Übernahme von CureVac sorgt für strategischen Schub (Aktiencheck)
|
|
New York (www.aktiencheck.de) - BioNTech-Aktienanalyse von H.C. Wainwright & Co.:
Die Analysten von H.C. Wainwright haben das Kursziel für die Aktie von BioNTech SE (ISIN: US09075V1026, WKN: A2PSR2, Ticker-Symbol: 22UA, NASDAQ-Symbol: BNTX) von 145 auf 138 USD gesenkt und bestätigen zugleich ihre Kaufempfehlung ("buy") für die Papiere. [mehr]...
|
|
|
|
|